A Pilot Study of Rituximab-Gemcitabine-Navelbine for Relapsed/Refractory Hodgkin's Lymphoma.

Trial Profile

A Pilot Study of Rituximab-Gemcitabine-Navelbine for Relapsed/Refractory Hodgkin's Lymphoma.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 20 Dec 2016

At a glance

  • Drugs Gemcitabine (Primary) ; Rituximab (Primary) ; Vinorelbine (Primary) ; Pegfilgrastim
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Mar 2012 Additional lead trial investigators (Stefanovic A) identified as reported by ClinicalTrials.gov.
    • 27 Apr 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top